MK-7845 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 of 8.7 nM[1].
References
[1] Valerie W Shurtleff, et al. Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic. J Med Chem. 2024 Feb 16. DOI:10.1021/acs.jmedchem.3c02248
